Search Result

Results for "

RdRp inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Angiotensin-converting Enzyme (ACE) (1) Antibiotic (1) Apoptosis (3) Arenavirus (1) Bacterial (5) Cytochrome P450 (1) Dengue Virus (4) DNA/RNA Synthesis (33) Drug Metabolite (3) Filovirus (2) Flavivirus (9) HBV (1) HCV (17) HCV Protease (3) Influenza Virus (15) Isotope-Labeled Compounds (3) Nucleoside Antimetabolite/Analog (3) Parasite (3) Phosphatase (3) Reference Standards (4) Reverse Transcriptase (4) RSV (6) SARS-CoV (33) Sirtuin (3) Thyroid Hormone Receptor (2) TNF Receptor (2) Topoisomerase (3) Virus Protease (4)
By Research Areas:	Cancer (5) Cardiovascular Disease (3) Endocrinology (2) Infection (66) Inflammation/Immunology (1)
Click Chemistry:	Azide (3)
Oligonucleotides:	Nucleoside Analogs (1) Cytidine (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155488

SHEN26 ATV014	SARS-CoV	Infection
SHEN26 (ATY014) is a potent and orally active *RdRp* inhibitor, with an IC₅₀ for SARS-CoV-2 is 1.36 μM. SHEN26 is a 5’-cyclohexanecarboxylate derivative of GS-441524 (HY-103586). SHEN26 inhibits viral nucleic acid synthesis to achieve antiviral effects. SHEN26 can be used for the research of coronavirus disease 2019 (COVID-19) .

HY-139442

RdRP-IN-2	SARS-CoV	Infection
RdRP-IN-2 is a RNA dependent RNA polymerase (RdRp) inhibitor. RdRP-IN-2 significantly inhibits SARS-CoV-2 RdRp with an IC₅₀ of 41.2 μM.RdRP-IN-2 also inhibits Feline coronavirus (FIPV) replication .

HY-154990

RdRP-IN-7	SARS-CoV	Infection
RdRP-IN-7 is a RNA-dependent RNA polymerase (RdRp) inhibitor that shows the inhibition of SARS-CoV-2 infection with an IC₅₀ of 8.2 μM, an IC₉₀ of 14.1 μM and an CC₉₀ of 79.1 μM. RdRP-IN-7 can be used for antiviral research .

HY-16750

Radalbuvir GS-9669	HCV	Infection
Radalbuvir (GS-9669) is a non-nucleoside inhibitor of nonstructural protein 5B (NS5B) RNA-dependent RNA polymerase (RdRp). Radalbuvir shows strong anti-HCV potency (GT1a intrinsic EC₅₀ = 2.9 nM, GT1b EC₅₀ = 6 nM) .

HY-152239

RdRP-IN-5	Influenza Virus	Infection
RdRP-IN-5 (compound 20) is a potent influenza virus RNA-dependent RNA polymerase (RdRP) inhibitor. RdRP-IN-5 can be used in research of influenza virus .

HY-152239B

trans-RdRP-IN-5	Influenza Virus	Infection
trans-RdRP-IN-5 (compound 18) is a potent influenza virus RNA-dependent RNA polymerase (RdRP) inhibitor. trans-RdRP-IN-5 can be used in research of influenza virus .

HY-152239A

cis-RdRP-IN-5	Influenza Virus	Infection
cis-RdRP-IN-5 (compound 19) is a potent influenza virus RNA-dependent RNA polymerase (RdRP) inhibitor. cis-RdRP-IN-5 can be used in research of influenza virus .

HY-154989

RdRP-IN-6	DNA/RNA Synthesis	Infection Cancer
RdRP-IN-6 (compound 27) inhibits RNA dependent-RNA polymerase (RdRp) with an IC₉₀ value of 14.1 μM. RdRP-IN-6 can be used for research on antiviral and anticancer .

HY-115730

RdRP-IN-3	DNA/RNA Synthesis Influenza Virus	Infection
RdRP-IN-3 is a promising anti-influenza agent candidate by inhibiting the activity of RNA-dependent RNA polymerase (RdRp).

HY-162793

RdRP-IN-8	Influenza Virus	Infection
RdRP-IN-8 (compound 45) is an anti-influenza virus compound. RdRP-IN-8 inhibits viral RNA-dependent RNA polymerase (RdRP) activity by disrupting heterodimerization of PA and PB1 subunits (EC₅₀=0.13 μM) .

HY-173134

SARS-CoV-2 RdRp-IN-1	SARS-CoV	Infection
SARS-CoV-2 RdRp-IN-1 (Compound PAP-2) is a potent SARS-CoV-2 RdRp inhibitor, with an EC₅₀ of 1.11 μM. SARS-CoV-2 RdRp-IN-1 can bind directly to SARS-CoV-2 RdRp, fully resistance to the exoribonuclease (ExoN) and exhibit broad spectrum anti-CoV activities .

HY-126303

GS-443902 GS-441524 triphosphate; Remdesivir metabolite	DNA/RNA Synthesis SARS-CoV RSV HCV Drug Metabolite	Infection
GS-443902 (GS-441524 triphosphate) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC₅₀s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively. GS-443902 is the active triphosphate metabolite of Remdesivir .

HY-170649

RdRP-IN-9	SARS-CoV	Infection
RdRP-IN-9 (Compound 6b) is a reversible covalent allosteric inhibitor of *RdRp. RdRP-IN-9 demonstrates high anti-coronavirus activity, with an EC₅₀* value of 0.68 μM against HCoV-OC43 RdRP-IN-9 exerts a more prolonged antiviral effect by reversibly acylating Cys12 in the NiRAN domain of non-structural protein 12 (nsp 12) and exhibits synergistic anti-coronavirus activity with Molnupiravir (HY-135853) .

HY-144668

RdRP-IN-4	Influenza Virus	Infection
RdRP-IN-4 (compound 11q), an aryl benzoyl hydrazide analog, is an orally active influenza A virus RNA-dependent RNA polymerase (RdRp) inhibitor by interacting with the PB1 subunit. RdRP-IN-4 exhibits potent inhibitory activity against the avian H5N1 flu strain with an EC50 of 18 nM in MDCK cells. RdRP-IN-4 displays excellent potency against the the H1N1 (A/PR/8/34) Flu A strain and Flu B strain (B/Lee/1940) with EC50 values of 53 nM and 20 nM, respectively. RdRP-IN-4 significantly inhibits the expression level of viral nucleoprotein (NP) in a dose-dependent manner. RdRP-IN-4 exhibits significant antiviral activity in infected mice .

HY-126303C

GS-443902 trisodium 10+ Cited Publications GS-441524 triphosphate trisodium; Remdesivir metabolite trisodium	DNA/RNA Synthesis SARS-CoV RSV HCV Drug Metabolite	Infection
GS-443902 trisodium (GS-441524 triphosphate trisodium) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC₅₀s of 1.1 μM, 5 μM for RSV RdRp and HCV RdRp, respectively. GS-443902 trisodium is the active triphosphate metabolite of Remdesivir (GS-5734) .

HY-100749

HeE1-2Tyr 1 Publications Verification	Flavivirus Dengue Virus SARS-CoV	Infection
HeE1-2Tyr, a pyridobenzothiazole compound, is a flavivirus RNA dependent RNA polymerases (RdRp) inhibitor. HeE1-2Tyr significantly inhibits West Nile, Dengue and SARS-CoV-2 RdRps (IC₅₀ of 27.6 μM) activity in vitro .

HY-13247

Setrobuvir ANA598	DNA/RNA Synthesis HCV SARS-CoV	Infection
Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC₅₀s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 *RdRp* and induces RdRp inhibition .

HY-134665

NITD-2	Flavivirus Dengue Virus DNA/RNA Synthesis	Infection
NITD-2, a dengue virus (DENV) polymerase inhibitor, inhibits the DENV RdRp-mediated RNA elongation. NITD-2 penetrates cell membrane poorly .

HY-134909

AS-136A	DNA/RNA Synthesis	Infection
AS-136A is an orally active non-nucleoside inhibitor of the measles virus RNA-dependent RNA polymerase *(RdRp)* with an IC₅₀ of 2 µM for measles virus .

HY-150234

LabMol-319	Virus Protease Flavivirus	Infection
LabMol-319 is a potent zika virus (ZIKV) NS5 RdRp inhibitor with an IC₅₀ of 1.6 μM. LabMol-319 is an antiviral agent .

HY-131603

Lamivudine triphosphate 3TCTP	Reverse Transcriptase HCV HBV SARS-CoV	Infection
Lamivudine triphosphate (3TCTP) is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate inhibits the Reverse Transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA .

HY-156440

7-51A	Influenza Virus	Infection
7-51A is a potent PB2 inhibitor with a KD value of 1.64 nM as determined by ITC. PB2 is an essential subunit of influenza RNA-dependent RNA polymerase (RdRP).

HY-160704

CMX-521	Nucleoside Antimetabolite/Analog	Infection
CMX-521, a nucleoside analog, is a potent inhibitor for RNA-dependant RNA polymerase (RdRp) of norovirus. CMX-521 suppresses murine norovirus (MNV) and human norovirus .

HY-14768

Favipiravir Maximum Cited Publications 45 Publications Verification T-705	DNA/RNA Synthesis Influenza Virus SARS-CoV Bacterial	Infection
Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC₅₀ of 341 nM.

HY-14768A

Favipiravir sodium T-705 sodium	DNA/RNA Synthesis Influenza Virus SARS-CoV Bacterial	Infection
Favipiravir (T-705) sodium is an inhibitor of viral RNA polymerase (RNA polymerase), which is converted into its active form Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the activity of influenza virus RNA-dependent RNA polymerase (RdRP) with an IC₅₀ of 341 nM .

HY-134991

3'-Deoxy-GTP 3′-Deoxyguanosine 5′-triphosphate	Dengue Virus DNA/RNA Synthesis Nucleoside Antimetabolite/Analog	Infection
3'-Deoxy-GTP (3′-Deoxyguanosine 5′-triphosphate), an analog of GTP, is a RNA chain terminator and suppresses RNA synthesis. 3'-Deoxy-GTP inhibits DENV NS5 RdRp (IC₅₀: 0.02 μM) .

HY-162924

SARS-CoV-IN-6	SARS-CoV	Infection
SARS-CoV-IN-6 (Compound 17) is an inhibitor of SARS-CoV-1 and SARS-CoV-2 *RdRp, with an IC₅₀* value of 7.8 μM against SARS-CoV-2 RdRp. SARS-CoV-IN-6 reduces cytopathic effects in cells infected with SARS-CoV-1 and SARS-CoV-2 replicon-based single-round infectious particles (SRIPs), and inhibits SARS-CoV N protein expression, with EC₅₀ values of 0.12 µM for SARS-CoV-1 replicon-based SRIPs and 1.47 µM for SARS-CoV-2 replicon-based SRIPs .

HY-155053

ZIKV-IN-6	Flavivirus DNA/RNA Synthesis	Inflammation/Immunology
ZIKV-IN-6 (compound 22) is an inhibitor of Zika virus (ZIKV), with low cytotoxicity (CC₅₀＞50 μM). ZIKV-IN-6 binds to ZIKV RdRp directly and inhibits viral RNA synthesis by ZIKV NS5. ZIKV-IN-6 suppresses the excessive inflammatory response and pyroptosis .

HY-134991A

3'-Deoxy-GTP trisodium 3′-Deoxyguanosine 5′-triphosphate trisodium	Dengue Virus DNA/RNA Synthesis Nucleoside Antimetabolite/Analog	Infection
3'-Deoxy-GTP (3′-Deoxyguanosine 5′-triphosphate) trisodium, an analog of GTP, is a RNA chain terminator and suppresses RNA synthesis. 3'-Deoxy-GTP trisodium inhibits DENV NS5 RdRp (IC₅₀: 0.02 μM) .

HY-131976

BVDV-IN-1	Flavivirus	Infection
BVDV-IN-1 is a non-nucleoside inhibitor (NNI) of bovine viral diarrhea virus (BVDV), with an EC₅₀ of 1.8 μM. BVDV-IN-1 directly binds to a hydrophobic pocket of the BVDV RdRp. BVDV-IN-1 has antiviral activity against BVDV resistant to NNI thiosemicarbazone (TSC) .

HY-159890

MTI013	SARS-CoV	Infection
MTI013 is a selective SARS-CoV-2 nsp14 Mtase inhibitor (IC₅₀: 2.98 μM) and an antiviral agent (IC₅₀: 10.33 μM in HCoV-229E-infected Huh7 cells). MTI013 also shows a synergistic antiviral effect with the RdRp inhibitor SHEN26 (HY-155488) .

HY-14768R

Favipiravir (Standard) T-705 (Standard)	Reference Standards DNA/RNA Synthesis Influenza Virus SARS-CoV Bacterial	Infection
Favipiravir (Standard) is the analytical standard of Favipiravir. This product is intended for research and analytical applications. Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC₅₀ of 341 nM.

HY-75800

Lomibuvir 2 Publications Verification VX-222	DNA/RNA Synthesis HCV	Infection
Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a K_d of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC₅₀ of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis .

HY-151526

LabMol-301	Virus Protease Flavivirus	Infection
LabMol-301 inhibits both NS5 RdRp and NS2B-NS3pro activity (IC₅₀: 0.8 and 7.4 μM, respectively). LabMol-301 has a cytoprotective effect and prevents Zika virus (ZIKV)-induced cell death .

HY-115929

DENV-IN-4	DNA/RNA Synthesis	Infection
DENV-IN-4 is a potent DENV inhibitor (DENV EC₅₀=4.79 μM, Vero CC₅₀>100 μM, SI>20.9). DENV-IN-4 can inhibit the expression level of DENV2 with concentration-dependence and reduce RNA-dependent RNA polymerase (RdRp) enzymatic activity. DENV-IN-4 has antiviral effect .

HY-174370

MePT-S-N-Pme	SARS-CoV	Infection
MePT-S-N-Pme is an inhibitor of SARS-CoV-2 RdRp activity. MePT-S-N-Pme demonstrates a significant reduced reporter activity with an IC₅₀ of 7 μM in HEK 293 cells. MePT-S-N-Pme has a slight inhibitory effect on nucleotidyltransferase activity. MePT-S-N-Pme significantly inhibits SARS-CoV-2 replication in vitro .

HY-157022

SARS-CoV-2-IN-67	SARS-CoV	Infection
SARS-CoV-2-IN-67 (Compound 16), a vitamin K derivatives, has anti-SARS-CoV-2 activity (EC₅₀: 64.8 μM in VeroE6/TMPRSS2 cells). SARS-CoV-2-IN-67 inhibits SARS-CoV-2 RdRp activity .

HY-W769714

Favipiravir-13C3 T-705-¹³C₃	Isotope-Labeled Compounds Antibiotic Bacterial	Infection
Favipiravir- ¹³C3 is the ¹³C labeled isotope of Favipiravir- ¹³C3(HY-14768 ).Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC₅₀ of 341 nM.

HY-168510

ATV03	Influenza Virus	Infection
ATV03 is an anti-influenza virus agent with excellent anti-influenza A and B virus activity. ATV03 inhibits anti-influenza A (H3N2) and anti-influenza B with EC₅₀ values of 0.78 nM and 2.02 nM, respectively. ATV03 exerts anti-influenza activity by inhibiting polymerase acidic protein (PA) and RNA-dependent RNA polymerase (RdRp), as well as disrupting nuclear protein .

HY-14768S

Favipiravir-13C15N T-705-¹³C¹⁵N	Isotope-Labeled Compounds Bacterial DNA/RNA Synthesis SARS-CoV Influenza Virus	Infection
Favipiravir- ¹³C ¹⁵N (T-705- ¹³C ¹⁵N) is ¹³C and ¹⁵N labeled Favipiravir. Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC₅₀ of 341 nM.

HY-B1201

Tiratricol 1 Publications Verification 3,3',5-Triiodothyroacetic acid	Flavivirus Thyroid Hormone Receptor TNF Receptor	Endocrinology
Tiratricol is an orally available thyroid hormone analog that inhibits pituitary thyroid-stimulating hormone secretion. Tiratricol is an intracellular toxin neutralizer that inhibits LPS and lipid A cytotoxicity with IC₅₀s of 20 μM and 32 μM, respectively. Tiratricol reduces TNF production in lipopolysaccharide-stimulated macrophages. Tiratricol also has antiviral activity and is an inhibitor of yellow fever virus (Flavivirus). It can bind to the RdRp domain of the viral NS5 protein to hinder YFV replication. .

HY-75800R

Lomibuvir (Standard)	DNA/RNA Synthesis HCV	Infection
Lomibuvir (Standard) is the analytical standard of Lomibuvir. This product is intended for research and analytical applications. Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis .

HY-10118

Filibuvir 2 Publications Verification	HCV DNA/RNA Synthesis	Infection
Filibuvir is an orally active, selective non-nucleoside inhibitor of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp). Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC₅₀s of 59 nM for both isoforms, respectively . Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation .

HY-168473

13-TP	SARS-CoV DNA/RNA Synthesis	Infection
13-TP is an inhibitor of SARS-CoV-2. 13-TP effectively inhibits the SARS-CoV-2 central replication transcription complex (C-RTC, nsp12-nsp7-nsp82) catalyzed in vitro RNA synthesis. 13-TP completely inhibits the RdRp polymerization activity. 13-TP blocks the full extension of some of the primer RNA .

HY-151254

CYP2C19-IN-1	Cytochrome P450 Influenza Virus DNA/RNA Synthesis	Infection
CYP2C19-IN-1 (compound 20d) is a potent CYP2C19 inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C19-IN-1 inhibits RNA-dependent RNA polymerase (RdRP) with a K_i value of 6.16 µM. CYP2C19-IN-1 can be used in study of anti-ZIKV .

HY-162719

RH12	SARS-CoV	Infection
RH12 is a dual inhibitor for SARS-CoV-2 related RNA-dependent RNA polymerase (RdRp, IC₅₀ is 4.42 nM) and human transmembrane serine protease 2 (TMPRSS2, IC₅₀ is 4.2 nM). RH12 exhibits antiviral efficacy. RH12 inhibits viral replication and absorption, and exhibits a 90.5% virucidal effects on Vero-E6 cells. RH12 inhibits cell viability of Calu-3 with an IC₅₀ of 17.5 nM .

HY-10241

Simeprevir 40+ Cited Publications TMC435; TMC435350	HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (M ^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-10241A

Simeprevir sodium TMC435 sodium; TMC435350 sodium	HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the main protease (M ^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-146246

EIDD-2749 3 Publications Verification 4'-FlU; 4'-Fluorouridine	RSV SARS-CoV HCV	Infection
EIDD-2749 (4'-Fluorouridine) is an orally active *RdRp* inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses .

HY-B1201R

Tiratricol (Standard) 3,3',5-Triiodothyroacetic acid (Standard)	Flavivirus Thyroid Hormone Receptor Reference Standards TNF Receptor	Endocrinology
Tiratricol (Standard) is the analytical standard of Tiratricol. This product is intended for research and analytical applications. Tiratricol is an orally available thyroid hormone analog that inhibits pituitary thyroid-stimulating hormone secretion. Tiratricol is an intracellular toxin neutralizer that inhibits LPS and lipid A cytotoxicity with IC₅₀s of 20 μM and 32 μM, respectively. Tiratricol reduces TNF production in lipopolysaccharide-stimulated macrophages. Tiratricol also has antiviral activity and is an inhibitor of yellow fever virus (Flavivirus). It can bind to the RdRp domain of the viral NS5 protein to hinder YFV replication. .

Cat. No.	Product Name	Chemical Structure

HY-W769714

Favipiravir-13C3
Favipiravir- ¹³C3 is the ¹³C labeled isotope of Favipiravir- ¹³C3(HY-14768 ).Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC₅₀ of 341 nM.

HY-14768S

Favipiravir-13C15N

Favipiravir- ¹³C ¹⁵N (T-705- ¹³C ¹⁵N) is ¹³C and ¹⁵N labeled Favipiravir. Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC₅₀ of 341 nM.

HY-10241S

Simeprevir-13C,d3

Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

Cat. No.	Product Name		Classification

HY-10444

R-1479 3 Publications Verification 4'-Azidocytidine		Azide
R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of HCV. R-1479 inhibits HCV replication in the HCV subgenomic replicon system (IC₅₀=1.28 μM) . R-1479 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-10443

Balapiravir 3 Publications Verification Ro 4588161; R1626		Azide
Balapiravir (Ro 4588161; R1626) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir has anti-HCV activity . Balapiravir is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-10443A

Balapiravir hydrochloride Ro 4588161 hydrochloride; R1626 hydrochloride		Azide
Balapiravir hydrochloride (Ro 4588161 hydrochloride; R1626 hydrochloride) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir hydrochloride has anti-HCV activity . Balapiravir (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Cat. No.	Product Name		Classification

HY-10444

R-1479 3 Publications Verification 4'-Azidocytidine		Nucleoside Analogs Cytidine
R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of HCV. R-1479 inhibits HCV replication in the HCV subgenomic replicon system (IC₅₀=1.28 μM) . R-1479 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: